A phase I study of trastuzumab-MCC-DM1 (T-DM1), a first-in-class HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+metastatic breast cancer (BC)

被引：0
|
作者：
Beeram, M.
Krop, I.
Modi, S.
Tolcher, A.
Rabbee, N.
Girish, S.
Tibbitts, J.
Holden, S.
Lutzker, S.
Burris, H.
机构：
[1] Inst Drug Dev, San Antonio, TX USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[4] Genentech Inc, San Francisco, CA 94080 USA
[5] Sarah Cannon Canc Ctr, Nashville, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1042
引用
收藏
页数：1
相关论文
共 50 条
  • [11] A Phase II Study of Trastuzumab-DM1 (T-DM1), a Novel HER2 Antibody-Drug Conjugate, in Patients Previously Treated with Lapatinib, Trastuzumab, and Chemotherapy
    Krop, I
    LoRusso, P.
    Miller, K. D.
    Modi, S.
    Yardley, D.
    Rodriguez, G.
    Agresta, S.
    Zheng, M.
    Amler, L.
    Rugo, H.
    CANCER RESEARCH, 2009, 69 (24) : 795S - 795S
  • [12] A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients (pts) with advanced HER2+breast cancer (BC)
    Holden, S. N.
    Beeram, M.
    Krop, I. E.
    Burris, H. A., III
    Birkner, M.
    Girish, S.
    Tibbitts, J.
    Lutzker, S. G.
    Modi, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [13] A phase I study of a first-in-class HER2 antibody-drug conjugate in patients with HER2-overexpressing metastatic breast cancer.
    Burris, H. A.
    Krop, I. E.
    Modi, S.
    Rodon, J.
    Lutzker, S. G.
    Holden, S. N.
    Bhattacharya, S.
    Sliwkowski, M. X.
    Beeram, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S104 - S104
  • [14] Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
    Krop, Ian E.
    Beeram, Muralidhar
    Modi, Shanu
    Jones, Suzanne F.
    Holden, Scott N.
    Yu, Wei
    Girish, Sandhya
    Tibbitts, Jay
    Yi, Joo-Hee
    Sliwkowski, Mark X.
    Jacobson, Fred
    Lutzker, Stuart G.
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) : 2698 - 2704
  • [15] Phase I study of BYL719 and trastuzumab-MCC-DM1 (T-DM1) in HER2-positive metastatic breast cancer (MBC) patients with progression on trastuzumab and taxane-based therapy
    Jain, Sarika
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [16] Dynamics of Endocytosis and Degradation of Antibody-Drug Conjugate T-DM1 in HER2 Positive Cancer Cells
    Liang, Keying
    Mei, Shengsheng
    Gao, Xiangzheng
    Peng, Shanshan
    Zhan, Jinbiao
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2021, 15 : 5135 - 5150
  • [17] Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer
    Baron, Jessica M.
    Boster, Bonnie L.
    Barnett, Chad M.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2015, 21 (02) : 132 - 142
  • [18] Quantitative assessment of HER2 status and correlation with efficacy for patients (pts) with metastatic breast cancer (MBC) in a phase II study of trastuzumab-DM1 (T-DM1)
    Krop, I. E.
    Burris, H. A.
    Rugo, H.
    O'Shaughnessy, J.
    Vogel, C. L.
    Amler, L.
    Strauss, A.
    Wong, E. K.
    Klencke, B.
    Pippen, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [19] Efficacy of trastuzumab emtansine (T-DM1) in patients (pts) with HER2+metastatic breast cancer (MBC) previously treated with pertuzumab (P).
    Urruticoechea, Ander
    Im, Seock-Ah
    Munoz, Montserrat
    Baselga, Jose
    Yardley, Denise A.
    Heeson, Sarah
    Jones, Sarah
    Knott, Adam
    Douthwaite, Hannah
    Crnjevic, Tanja Badovinac
    Swain, Sandra M.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [20] Ethnic sensitivity assessment of the antibody-drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer
    Li, Chunze
    Wang, Bei
    Lu, Dan
    Jin, Y.
    Gao, Yuying
    Matsunaga, Kiyoshi
    Igawa, Yuriko
    Nijem, Ihsan
    Lu, Michael
    Strasak, Alexander
    Chernyukhin, Nataliya
    Girish, Sandhya
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (03) : 547 - 558
12345